Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could predict your next heart attack

NCT ID NCT05175261

Diagnosis Sponsor: Prolocor, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new blood test that measures a protein on platelets called FcγRIIa. Researchers wanted to see if higher levels of this protein could predict future heart attacks, strokes, or death in people who had already had a heart attack. About 764 participants were enrolled and followed for up to 18 months. The goal is to develop a risk score combining this test with other factors to guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prolocor pFCG test (a blood test measuring platelet FcγRIIa levels)
What this could lead to
If successful, this test could help doctors better identify heart attack survivors at highest risk of future heart attacks or strokes, allowing for more personalized care.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

764 people

The number who actually took part.

Started

Jan 2022

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 800 male and female subjects with confirmed MI \[ST-segment elevation MI (STEMI) or non-ST-segment elevation MI (NSTEMI)\] will be enrolled before hospital discharge for the index event.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Type 1 Myocardial Infarction (STEMI and NSTEMI) 2. Must have ≥ 2 of the following risk factors: 1. Age ≥ 65 2. Multi-vessel coronary artery disease (MVD) defined as ≥2 vessels or left main with a stenosis ≥50% 3. Chronic kidney disease (CKD) defined as estimated glomerular filtration rate (GFR) ˂ 60 mL/min/1.73 m2 4. Diabetes mellitus (DM) 5. Prior MI 3. Must agree to participate in the study, to comply with all study procedures and follow-up contact 4. Signed the informed consent form Exclusion Criteria: 1. Requirement for treatment with full dose anticoagulant therapy (e.g., for atrial fibrillation) 2. Participation in another trial in which the subject is known to receive or could receive anticoagulant or antiplatelet treatment as part of the trial intervention. 3. Non-cardiovascular conditions that, in the judgment of the investigator, will limit survival to less than 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSTEMI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSTEMI STEMI

Contacts and locations

Locations

  • University of Vermont

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.